Economic Burden of Medically Attended Respiratory Syncytial Virus Infections Among Privately Insured Children Under 5 Years of Age in the USA.
Humans
Respiratory Syncytial Virus Infections
/ economics
Infant
Child, Preschool
United States
/ epidemiology
Cost of Illness
Female
Male
Health Care Costs
/ statistics & numerical data
Insurance, Health
/ economics
Hospitalization
/ economics
Infant, Newborn
Respiratory Tract Infections
/ economics
Incidence
Respiratory Syncytial Virus, Human
/ isolation & purification
RSV
cost
economic burden
episode of care
respiratory syncytial virus
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
revised:
31
05
2024
received:
09
04
2024
accepted:
03
06
2024
medline:
2
7
2024
pubmed:
2
7
2024
entrez:
1
7
2024
Statut:
ppublish
Résumé
The cost of medically attended RSV LRI (lower respiratory infection) is critical in determining the economic value of new RSV immunoprophylaxes. However, most studies have focused on intermittent RSV encounters, not the episode of care that captures the entirety of RSV illness. We created age- and condition-specific cohorts of children under 5 years of age using MarketScan® data (2015-2019). We contrasted aggregating healthcare costs over RSV-LRTI episodes to ascertaining costs based on RSV-specific encounters only. Economic burden was estimated by multiplying costs per encounter or per episode by their respective incidence rates. Average cost was higher per episode than per encounter regardless of settings (inpatient: $28,586 vs. $18,056 and outpatient/ED: $2099 vs. $407 for infants). Across ages, the economic burden was highest for infants and RSV-LRTI requiring inpatient care, but the burden in outpatient/ED settings was disproportionately higher than costs due to higher incidence rates (for inpatient vs. outpatient episodes: $226,403 vs. $101,269; for inpatient vs. outpatient encounters: $151,878 vs. $38,819 per 1000 infant-years). For high-risk children, cost and burden were up to 3-10 times higher, respectively. With a comprehensive stratification by settings and risk condition, the encounter- versus episode-based estimates provide a robust range for policymakers' economic appraisal of new RSV immunoprophylaxes.
Sections du résumé
BACKGROUND
BACKGROUND
The cost of medically attended RSV LRI (lower respiratory infection) is critical in determining the economic value of new RSV immunoprophylaxes. However, most studies have focused on intermittent RSV encounters, not the episode of care that captures the entirety of RSV illness.
METHODS
METHODS
We created age- and condition-specific cohorts of children under 5 years of age using MarketScan® data (2015-2019). We contrasted aggregating healthcare costs over RSV-LRTI episodes to ascertaining costs based on RSV-specific encounters only. Economic burden was estimated by multiplying costs per encounter or per episode by their respective incidence rates.
RESULTS
RESULTS
Average cost was higher per episode than per encounter regardless of settings (inpatient: $28,586 vs. $18,056 and outpatient/ED: $2099 vs. $407 for infants). Across ages, the economic burden was highest for infants and RSV-LRTI requiring inpatient care, but the burden in outpatient/ED settings was disproportionately higher than costs due to higher incidence rates (for inpatient vs. outpatient episodes: $226,403 vs. $101,269; for inpatient vs. outpatient encounters: $151,878 vs. $38,819 per 1000 infant-years). For high-risk children, cost and burden were up to 3-10 times higher, respectively.
CONCLUSIONS
CONCLUSIONS
With a comprehensive stratification by settings and risk condition, the encounter- versus episode-based estimates provide a robust range for policymakers' economic appraisal of new RSV immunoprophylaxes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13347Subventions
Organisme : Merck Sharp & Dohme LLC
Informations de copyright
© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
L. M. Taussig, A. L. Wright, C. J. Holberg, M. Halonen, W. J. Morgan, and F. D. Martinez, “Tucson Children's Respiratory Study: 1980 to Present,” The Journal of Allergy and Clinical Immunology 111, no. 4 (2003): 661–675.
Y. Zhang, S. K. Sakthivel, A. Bramley, et al., “Serology Enhances Molecular Diagnosis of Respiratory Virus Infections Other Than Influenza in Children and Adults Hospitalized With Community‐Acquired Pneumonia,” Journal of Clinical Microbiology 55, no. 1 (2017): 79–89.
A. K. Singh, A. Jain, B. Jain, et al., “Viral Aetiology of Acute Lower Respiratory Tract Illness in Hospitalised Paediatric Patients of a Tertiary Hospital: One Year Prospective Study,” Indian Journal of Medical Microbiology 32, no. 1 (2014): 13–18.
E. K. Miller, T. Gebretsadik, K. N. Carroll, et al., “Viral Etiologies of Infant Bronchiolitis, Croup and Upper Respiratory Illness During 4 Consecutive Years,” The Pediatric Infectious Disease Journal 32, no. 9 (2013): 950–955.
H. E. Stempel, E. T. Martin, J. Kuypers, J. A. Englund, and D. M. Zerr, “Multiple Viral Respiratory Pathogens in Children With Bronchiolitis,” Acta Paediatrica (Oslo, Norway: 1992) 98, no. 1 (2009): 123–126.
D. M. Weinberger, K. P. Klugman, C. A. Steiner, L. Simonsen, and C. Viboud, “Association Between Respiratory Syncytial Virus Activity and Pneumococcal Disease in Infants: A Time Series Analysis of US Hospitalization Data,” PLoS Medicine 12, no. 1 (2015): e1001776.
American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee, “Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection,” Pediatrics 134, no. 6 (2014): 1221–1420.
The American Academy of Pediatrics, “AAP Publications Reaffirmed,” Pediatrics 144, no. 2 (2019): e2021052583.
M. Suh, N. Movva, L. C. Bylsma, J. P. Fryzek, and C. B. Nelson, “A Systematic Literature Review of the Burden of Respiratory Syncytial Virus and Health Care Utilization Among United States Infants Younger Than 1 Year,” The Journal of Infectious Diseases 226, no. Suppl 2 (2022): S195–S212.
D. M. Bowser, K. R. Rowlands, D. Hariharan, et al., “Cost of Respiratory Syncytial Virus Infections in US Infants: Systematic Literature Review and Analysis,” The Journal of Infectious Diseases 226, no. Suppl 2 (2022): S225–S235.
M. Toth, P. Moore, E. Tant, et al., “Early Impact of the Implementation of Medicaid Episode‐Based Payment Reforms in Arkansas,” Health Services Research 55, no. 4 (2020): 556–567.
The Centers for Medicare and Medicaid Services, “Quality Payment Programs: 2020 Episode‐Based Cost Measures Field Testing Wave 3 Measure Development Process,” accessed July 25, 2021, https://www.cms.gov/files/document/macra‐cmft‐ebcm‐process‐2020.pdf.
State, of Tennessee Health Care Innovation Initiative, “Executive Summary: Bronchiolitis Episode,” accessed October 16, 2021, https://www.tn.gov/content/dam/tn/tenncare/documents2/BRONCSumm2020v30.pdf.
State of Tennessee Health Care Innovation Initiative, “Executive Summary: Respiratory Infection Episode,” accessed October 16, 2021, https://www.tn.gov/content/dam/tn/tenncare/documents2/RISumm2020v40.pdf.
E. Hellsten and K. J. Sheehan, “Health Services Information: Key Concepts and Considerations in Building Episodes of Care From Administrative Data,” in Data and Measures in Health Services Research, eds. B. Sobolev, A. Levy, and S. Goring (Boston, MA: Springer US, 2016), 1–25.
National Institute for Health Care Reform, “Episode‐Based Payments: Charting a Course for Health Care Payment Reform,” accessed January 22, 2021, https://www.nihcr.org/publications/episode‐based‐payments/.
C. Hampp, T. L. Kauf, A. S. Saidi, and A. G. Winterstein, “Cost‐Effectiveness of Respiratory Syncytial Virus Prophylaxis in Various Indications,” Archives of Pediatrics & Adolescent Medicine 165, no. 6 (2011): 498–505.
C. Amand, S. Tong, A. Kieffer, and M. H. Kyaw, “Healthcare Resource Use and Economic Burden Attributable to Respiratory Syncytial Virus in the United States: A Claims Database Analysis,” BMC Health Services Research 18, no. 1 (2018): 294.
M. L. Forbes, C. B. Hall, A. Jackson, A. S. Masaquel, and P. J. Mahadevia, “Comparative Costs of Hospitalisation Among Infants at High Risk for Respiratory Syncytial Virus Lower Respiratory Tract Infection During the First Year of Life,” Journal of Medical Economics 13, no. 1 (2010): 136–141.
M. Goldstein, L. R. Krilov, J. Fergie, et al., “Respiratory Syncytial Virus Hospitalizations Among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012‐2016,” American Journal of Perinatology 35, no. 14 (2018): 1433–1442.
K. K. McLaurin, A. M. Farr, S. W. Wade, D. R. Diakun, and D. L. Stewart, “Respiratory Syncytial Virus Hospitalization Outcomes and Costs of Full‐Term and Preterm Infants,” Journal of Perinatology: Official Journal of the California Perinatal Association 36, no. 11 (2016): 990–996.
L. Palmer, C. B. Hall, J. P. Katkin, et al., “Healthcare Costs Within a Year of Respiratory Syncytial Virus Among Medicaid Infants,” Pediatric Pulmonology 45, no. 8 (2010): 772–781.
N. Shi, L. Palmer, B. C. Chu, et al., “Association of RSV Lower Respiratory Tract Infection and Subsequent Healthcare Use and Costs: A Medicaid Claims Analysis in Early‐Preterm, Late‐Preterm, and Full‐Term Infants,” Journal of Medical Economics 14, no. 3 (2011): 335–340.
D. L. Stewart, J. R. Romero, E. K. Buysman, A. W. Fernandes, and P. J. Mahadevia, “Total Healthcare Costs in the US for Preterm Infants With Respiratory Syncytial Virus Lower Respiratory Infection in the First Year of Life Requiring Medical Attention,” Current Medical Research and Opinion 25, no. 11 (2009): 2795–2804.
J. Ledbetter, L. Brannman, S. W. Wade, T. Gonzales, and A. M. Kong, “Healthcare Resource Utilization and Costs in the 12 Months Following Hospitalization for Respiratory Syncytial Virus or Unspecified Bronchiolitis Among Infants,” Journal of Medical Economics 23, no. 2 (2020): 139–147.
L. R. Krilov, J. Fergie, M. Goldstein, and L. Brannman, “Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations Among Preterm Infants,” American Journal of Perinatology 37, no. 2 (2020): 174–183.
V. V. Chirikov, E. A. F. Simões, A. Kuznik, Y. Kwon, and M. Botteman, “Economic‐Burden Trajectories in Commercially Insured US Infants With Respiratory Syncytial Virus Infection,” The Journal of Infectious Diseases 221, no. 8 (2020): 1244–1255.
P. Tran, S. Nduaguba, V. Diaby, et al., “RSV Incidence Among Privately Insured U.S. Children Under 5 Years of Age,” In RSVVW'21. Virtually, (2021).
V. J. Flaherman, A. I. Ragins, S. X. Li, P. Kipnis, A. Masaquel, and G. J. Escobar, “Frequency, Duration and Predictors of Bronchiolitis Episodes of Care Among Infants ≥32 Weeks Gestation in a Large Integrated Healthcare System: A Retrospective Cohort Study,” BMC Health Services Research 12 (2012): 144.
W. Cai, K. Tolksdorf, S. Hirve, et al., “Evaluation of Using ICD‐10 Code Data for Respiratory Syncytial Virus Surveillance,” Influenza and Other Respiratory Viruses 14, no. 6 (2020): 630–637.
A. Pisesky, E. I. Benchimol, C. A. Wong, et al., “Incidence of Hospitalization for Respiratory Syncytial Virus Infection Amongst Children in Ontario, Canada: A Population‐Based Study Using Validated Health Administrative Data,” PLoS ONE 11, no. 3 (2016): e0150416.
M. A. Hamilton, A. Calzavara, S. D. Emerson, et al., “Validating International Classification of Disease 10th Revision Algorithms for Identifying Influenza and Respiratory Syncytial Virus Hospitalizations,” PLoS ONE 16, no. 1 (2021): e0244746.
S. Nduaguba, P. Tran, and A. Winterstein, “Correction of Diagnostic Coding‐Based RSV Incidence Using NREVSS Data,” In Society for Epidemiologic Research Conference Chicago June 14‐17, (2022).
P. T. Tran, S. O. Nduaguba, V. Diaby, Y. Choi, and A. G. Winterstein, “RSV Testing Practice and Positivity by Patient Demographics in the United States: Integrated Analyses of MarketScan and NREVSS Databases,” BMC Infectious Diseases 22, no. 1 (2022): 681.
M. Moore, P. Little, K. Rumsby, et al., “Predicting the Duration of Symptoms in Lower Respiratory Tract Infection,” The British Journal of General Practice 58, no. 547 (2008): 88–92.